Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
News|Articles|May 16, 2018
Bench-Top System Streamlines Chromatography Operations
Author(s)Pharmaceutical Technology Editors
The ÄKTA pilot 600 from GE Healthcare is a lightweight bench-top chromatography system suited to streamline both GMP and non-GMP everyday operations.
The ÄKTA pilot 600 from GE Healthcare is a lightweight bench-top chromatography system suited to streamline both GMP and non-GMP everyday operations. The instrument’s modular design allows for functionality to be added or removed as user requirements change. The flow and pressure range support both production of technical batches and scale-up studies as well as small-scale production of GMP-grade material. The interactive process picture enables changes to be made in real-time, and deviations are quickly identified. The accuracy and range of the pumps facilitates precise gradient formation that supports a column sizes range of 26 to 200 mm i.d.
The system works with the company’s AxiChrom chromatography columns through the intelligent packing function and the packing port. Prepacked 1- and 2.5-L ReadyToProcess columns can also be used with the system.The compact design allows for easy movement and placement on a lab bench or a ReadyKart mobile station, with all functional parts placed on one side of the instrument for convenient access.
Source:
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.